Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

COPCOV trial

COPCOV logo 16x5

There are currently no proven vaccines or drugs for prevention of COVID-19. Chloroquine and hydroxychloroquine, drugs that have been used to treat malaria and a variety of rheumatological conditions have shown initial promise. Funded by the COVID-19 Bill & Melinda Gates Foundation, Wellcome and Mastercard Therapeutics Accelerator grant, the COPCOV study will enroll 40,000+ vital frontline health care workers and staff who have close contact with COVID-19 patients to determine whether chloroquine or hydroxychloroquine are effective in preventing COVID-19.

Watch a video explaining what happens when you enrol in COPCOV

COPCOV trial introduction

Professor Nick White tells us about the COPCOV trial that aims to determine whether chloroquine or hydroxychloroquine are effective in preventing COVID-19 in health care workers.


Principal Investigators

Investigators

Trial researchers